Abstract Background Limited data are available regarding asymptomatic COVID-19 among people with HIV (PWH). Data on a representative subset of PWH enrolled in REPRIEVE, a global clinical trial […]
Abstract Background We sought to explore multinational differences in functional status by Global Burden of Disease (GBD) regions in the REPRIEVE cohort. Methods REPRIEVE is a […]
Abstract Background Among ART-treated people with HIV (PWH), persistent systemic immune activation contributes to atherogenesis, cardiovascular disease (CVD) events, and mortality. Factors associated with key immune […]
Abstract Background People with HIV (PWH) are at increased risk for cardiovasvular disease (CVD) and sudden cardiac death. Prior work has suggested an association between HIV […]
Abstract Little is known regarding COVID-19 vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates […]
Abstract Background Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of […]
Abstract Background In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and HIV-related factors may contribute to future CV events in persons with HIV […]
Key Points Question What is the extent of coronary artery disease among people with well-controlled HIV and low to moderate risk of atherosclerotic cardiovascular disease (ASCVD), and […]
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 […]